Literature DB >> 24472639

Treatment modality: a predictor of continued tobacco use after treatment in patients with laryngeal cancer.

V Narwani1, M Harries2.   

Abstract

BACKGROUND: Laryngeal cancer patients who continue to smoke after treatment are at an elevated risk of mortality and morbidity. This study aimed to identify factors associated with continued tobacco use following treatment in patients with laryngeal cancer.
METHODS: A smoking behaviour questionnaire, a self-report measure, was sent to 112 patients who were diagnosed with laryngeal cancer during 2006-2011 at the Brighton and Sussex University Hospitals, Brighton, UK. Patient demographics, tumour and treatment-related variables, comorbidity and socio-economic status were obtained from the medical records.
RESULTS: Eighty-one per cent of patients responded to the survey; 22 per cent of these reported continued tobacco use after treatment. Treatment modality was found to be a predictor of post-therapeutic smoking (odds ratio: 4.9, p = 0.01); patients who received less invasive therapy (transoral laser microsurgery) were more likely to smoke after treatment.
CONCLUSIONS: The findings of this preliminary study suggest that treatment modality influences smoking behaviour in patients with laryngeal cancer, which may have important implications for the design of anti-smoking interventions.

Entities:  

Mesh:

Year:  2014        PMID: 24472639     DOI: 10.1017/S0022215113003344

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

1.  Predictors of post-treatment smoking and drinking behavior of head and neck cancer survivors: results of a population-based survey.

Authors:  Ulrike Schiller; Johanna Inhestern; Ulrike Burger; Susanne Singer; Orlando Guntinas-Lichius
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-02-13       Impact factor: 2.503

2.  Expression of p27 and PTEN and clinical characteristics in early laryngeal squamous cell carcinoma and their correlation with recurrence.

Authors:  Jun-Quan Yang; Zhen Liang; Meng Wu; Yu-Man Sun; Hong-Xia Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir: A retrospective case report.

Authors:  Guna Proboka; Agnija Rasa; Evija Olmane; Sergejs Isajevs; Andra Tilgase; Pēteris Alberts
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.